Laura Francis: Yes. Great, thanks, Drew, in terms of the environment, as you can see, we weren’t necessarily seeing an impact or any softness in any particular part of the market in the fourth quarter. And as I also shared for Q1, our expectation is to see even further acceleration of our year-over-year growth in Q1. And I do think, though, that the last part of your question is the right question. Our opportunity with Granite is quite unique, at least for us here at SI-BONE. With our core market and SI joint fusion and also the opportunity in trauma with fragility fracture, those are really markets that take time to develop versus in the case of Granite and adult deformity, it’s really more — is very surgeon that’s going to perform a long construct procedure and are they looking to use Granite for spino-pelvic fixation and fusion.
So there’s a much more potential opportunity for rapid uptake in our Granite product than there have been in our previous products. But the — what’s important here is that we have enough implants in the field. We have enough instrument trays in the field. And then also that we’re on the approved list at the various hospitals where these procedures are going to be performed. And I can tell you, we’ve made extraordinary progress just in the last few months when we spoke in November, that was a rate-limiting factor for us. But we started to — so even towards the middle of Q4, we were bringing in more implants, more trays and it’s giving us the ability to try and keep up with some of this demand. And so I’m feeling pretty confident that we can meet the demand for both implants and trade for our Granite product, but it’s definitely the — probably the primary point of focus on fully recognizing the opportunity that we have in front of us with Granite.
In addition, we’ve made great progress on making sure that Granite is on the approved list at these various hospitals. So we have approximately 2,500 hospitals now that have Granite on their approved list and we continue to tick through a few of them that are remaining at this point. But overall, we’re in a good spot there. So I think that, hopefully, that answers your question.
Drew Ranieri: Yes. Great color. Thank you. And maybe for Anshul, we’ve talked about guidance a few times tonight, but can you help us maybe frame volume growth, your expectations for volume growth in 2023, just coming off the strong fourth quarter and just help us kind of better contextualize what acceleration means in terms of volume growth? And then second, just any framework you can provide on CapEx for €˜23? Thanks for taking the questions.
Anshul Maheshwari: Yes. So in terms of our breakdown between volume and volume growth from a revenue growth perspective, Drew, our ASP assumptions are sort of having an ASP degradation that’s similar to what we’ve had sort of last 12 months, which is between that 4% to 5% ASP degradation is what’s put in there. So if you do the math of 17 to 19, that will give you an estimate of where the volume growth should be to be able to hit the low-end or the high -end of the range. And even within the U.S. and OUS, our expectation is that growth is going to be faster in the U.S., the OUS growth, like I said previously to an earlier question, would be a lot more muted and more back-half loaded as well. So that’s sort of on the volume side.
